| Compound Information | SONAR Target prediction | | Name: | MYRICETIN | | Unique Identifier: | SPE01504065 | | MolClass: | Checkout models in ver1.5 and ver1.0 | | Molecular Formula: | C15H10O8 | | Molecular Weight: | 308.156 g/mol | | X log p: | 9.93000000000001 (online calculus) | | Lipinksi Failures | 1 | | TPSA | 26.3 | | Hydrogen Bond Donor Count: | 0 | | Hydrogen Bond Acceptors Count: | 8 | | Rotatable Bond Count: | 1 | | Canonical Smiles: | Oc1cc(O)c2C(=O)C(O)=C(Oc2c1)c1cc(O)c(O)c(O)c1 | | Source: | ex Myrica spp | | Reference: | J Chem Soc 81: 203 (1902); PNAS 97: 4790 (2000) | | Therapeutics: | antiHIV, topoisomerase II inhibitor | | Generic_name: | 2-(3,4,5-TRIHYDROXYPHENYL)-3,5,7-TRIHYDR | | Chemical_iupac_name: | 3,5,7-TRIHYDROXY-2-(3,4,5-TRIHYDROXYPHENYL)-4H-CHROMEN-4-ONE | | Drug_type: | Experimental | | Drugbank_id: | EXPT02265 | | Drug_category: | Phosphatidylinositol 3-Kinase Catalytic Subu inhibitor | | Organisms_affected: | -1 |
| Species: |
4932 |
| Condition: |
FUR4 |
| Replicates: |
2 |
| Raw OD Value: r im |
0.4527±0.0268701 |
| Normalized OD Score: sc h |
1.0053±0.0203593 |
| Z-Score: |
0.1884±0.563804 |
| p-Value: |
0.695306 |
| Z-Factor: |
-14.8965 |
| Fitness Defect: |
0.3634 |
| Bioactivity Statement: |
Nonactive |
| Experimental Conditions | | | Library: | Spectrum | | Plate Number and Position: | 10|B7 | | Drug Concentration: | 50.00 nM | | OD Absorbance: | 600 nm | | Robot Temperature: | 25.60 Celcius | | Date: | 2006-03-22 YYYY-MM-DD | | Plate CH Control (+): | 0.039425±0.00182 | | Plate DMSO Control (-): | 0.44525000000000003±0.01755 | | Plate Z-Factor: | 0.7935 |
|  png
ps
pdf |
| DBLink | Rows returned: 3 | |
| 5280343 |
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one |
| 5281672 |
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one |
| 5284452 |
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one dihydrate |
| internal high similarity DBLink | Rows returned: 12 | 1 2 Next >> |
| active | Cluster 10732 | Additional Members: 22 | Rows returned: 8 | 1 2 Next >> |
|
